{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:07:29Z","timestamp":1790665649681,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,10,27]],"date-time":"2019-10-27T00:00:00Z","timestamp":1572134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The standard first\u2010line treatment for primary mediastinal B\u2010cell lymphoma (PMBCL) patients is rituximab\u2010based immunochemotherapy; however, this is not due to the result of randomized clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>We retrospectively investigated 53 PMBCL patient outcomes treated either with R\u2010CHOP\u201021 or DA\u2010EPOCH\u2010R\u201028. The primary endpoint was overall survival (OS). Secondary endpoints were complete remission (CR), overall response rate (ORR), progression\u2010free survival (PFS), and treatment\u2010related complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment with R\u2010CHOP\u201021 resulted in a 92.0% ORR (60% CR), while DA\u2010EPOCH\u2010R yielded a 92.6% ORR (70.4% CR). There were no differences in the occurrence of grade 3\u20104 hematological adverse events, but grade 1\u20102 cardiologic complications (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.003) were observed more frequently in the DA\u2010EPOCH\u2010R arm. Median PFS and OS were not achieved. The differences in estimated 12\u2010month PFS in R\u2010CHOP and DA\u2010EPOCH\u2010R group (87% vs 73.9%) and OS (100% vs 92%) were insignificant. Patients treated with R\u2010CHOP\u201021 and autologous hematopoietic stem cell transplantation (auto\u2010HSCT) had an improved OS (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.03) but not PFS (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.43) compared to those treated solely with R\u2010CHOP\u201021. No differences in PFS or OS were observed between patients treated with R\u2010CHOP\u201021\/auto\u2010HSCT and DA\u2010EPOCH\u2010R.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results of this study suggest that R\u2010CHOP\u201021 may be an alternative to DA\u2010EPOCH\u2010R treatment for PMBCL patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13337","type":"journal-article","created":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T10:23:23Z","timestamp":1570962203000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Outcomes of treatment with dose\u2010adjusted EPOCH\u2010R or R\u2010CHOP in primary mediastinal large B\u2010cell lymphoma"],"prefix":"10.1111","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-2718","authenticated-orcid":false,"given":"Agata","family":"Malenda","sequence":"first","affiliation":[{"name":"Department of Hematology Institute of Hematology and Transfusion Medicine Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Ko\u0142kowska\u2010Le\u015bniak","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Hematology and Transfusion Medicine Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Pu\u0142a","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Hematology and Transfusion Medicine Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"D\u0142ugosz\u2010Danecka","sequence":"additional","affiliation":[{"name":"Department of Hematology Jagiellonian University Cracow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Che\u0142stowska","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Hematology and Transfusion Medicine Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Ko\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Hematology and Transfusion Medicine Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Giza","sequence":"additional","affiliation":[{"name":"Department of Hematology Jagiellonian University Cracow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lech\u2010Mara\u0144da","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Hematology and Transfusion Medicine Warsaw Poland"},{"name":"Department of Hematology and Transfusion Medicine Centre of Postgraduate Medicine Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Hematology Jagiellonian University Cracow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Warzocha","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Hematology and Transfusion Medicine Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821201)50:11<2486::AID-CNCR2820501138>3.0.CO;2-G"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_2_7_5_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2017"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.01.009"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1855"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2479"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.04.006"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.298"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.322"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031074"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-077982"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq418"},{"issue":"2","key":"e_1_2_7_18_1","first-page":"8","article-title":"Mature response data from a phase 2 study of PI3K\u2010delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)\u2010refractory indolent B\u2010cell non\u2010Hodgkin lymphoma (iNHL)","volume":"12","author":"Gopal A","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj030"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.349"},{"issue":"12","key":"e_1_2_7_21_1","first-page":"1258","article-title":"Induction chemotherapy strategies for primary mediastinal large B\u2010cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients","volume":"87","author":"Zinzani PL","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.074"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.810738"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2685"},{"key":"e_1_2_7_25_1","first-page":"43.e","article-title":"The addition of rituximab to dose\u2010adjusted (DA)\u2010EPOCH obviates the need for radiation in the treatment of primary mediastinal large B\u2010cell lymphoma (PMBL): a prospective study of 58 patients","volume":"19","author":"Dunleavy K","year":"2008","journal-title":"Ann Oncol"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15051"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.111203"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.02.006"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14951"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.120"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.469.469"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13337","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T16:03:10Z","timestamp":1693843390000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,27]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1111\/ejh.13337"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13337","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,27]]},"assertion":[{"value":"2019-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}